MedPath

Clinical Trial News

FDA Approves First Fully Implantable Artificial Heart for End-Stage Patients

  • The FDA has approved the AbioCor Implantable Replacement Heart, the first completely implantable artificial heart, for patients with severe heart failure who are ineligible for a heart transplant.
  • The device is intended for individuals with acute heart failure who are not candidates for heart transplantation and have a life expectancy of less than a month.
  • Clinical trials demonstrated that the AbioCor extended survival by an average of 4.5 months, providing patients with valuable time with family and friends.
  • Abiomed Inc. developed the artificial heart, which replaces the patient's own heart and includes a power transfer coil, internal battery, and controller.

HonorHealth's Cancer Research Program: A Leader in Clinical Trials and Treatment Innovation

HonorHealth's cancer research program at the HonorHealth Research Institute is at the forefront of cancer treatment innovation, offering patients access to clinical trials from phase I to IV. The program emphasizes early drug development, providing patients with new medications and treatment approaches before they are widely available. With a comprehensive support system, including navigators and concierge services, HonorHealth is dedicated to advancing medical care and improving patient outcomes.

Ceftriaxone Shows Promise in Alleviating Fatigue in Post-Lyme Disease Syndrome

  • A randomized, double-blind, placebo-controlled trial assessed the efficacy of ceftriaxone in treating post-Lyme disease syndrome (PLS) patients with persistent fatigue.
  • Ceftriaxone therapy demonstrated a significant improvement in fatigue compared to placebo in PLS patients, as measured by a fatigue questionnaire.
  • The study found no beneficial effect of ceftriaxone on cognitive function or experimental measures of persistent infection in PLS patients.
  • Due to adverse events and the improvement of only fatigue, the study does not support routine antibiotic therapy with ceftriaxone for PLS patients.

Home-Based Exercise Program Significantly Reduces Knee Pain, Study Finds

A two-year study involving 786 participants with knee pain found that a simple home-based exercise program significantly reduces knee pain and improves physical function. The study highlights the importance of exercise adherence for pain reduction and suggests that social support alone does not improve health outcomes.

Intensive Chemo Shows Promise in Relapsed Ovarian Cancer

  • A new intensive chemotherapy regimen demonstrates high effectiveness in treating women with relapsed ovarian cancer after initial chemotherapy failure.
  • The treatment, combining cisplatin and etoposide, achieved an 80% tumor shrinkage rate, with 43% of patients showing complete remission.
  • The intensive regimen, involving weekly cisplatin administration, proved more effective than standard therapies, offering new hope for patients with limited options.
  • Researchers noted the treatment was well-tolerated, with manageable side effects, and the drugs are readily available for immediate patient benefit.

ASCO 2024: Lenvatinib plus Pembrolizumab Shows Superiority Over Sunitinib in Advanced Renal Cell Carcinoma

At the 2024 ASCO Annual Meeting, Dr. Viktor Grünwald presented findings from the CLEAR trial, highlighting the efficacy of lenvatinib plus pembrolizumab over sunitinib in treating advanced clear cell renal cell carcinoma. The combination therapy demonstrated significant improvements in overall survival, prolonged time to tumor progression across various organs, and a lower median tumor burden at disease progression.

Trending News

1

Lundbeck's Eptinezumab Shows Strong Efficacy in Asian Chronic Migraine Patients in Phase III SUNRISE Trial

2 days ago
2

Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Phase 3 Trials, Reducing Injection Burden by 300 Doses Annually

a day ago
3

Japanese Startup's Urine-Based Cancer Test Detects Stage 0 Lung Cancer in Hokkaido Pilot Study

2 days ago
4

Otsuka Pharmaceutical Secures Global Rights to HBM7020 BCMAxCD3 Bispecific T-Cell Engager for Autoimmune Diseases

18 hours ago
5

Novo Nordisk's Mim8 Shows Safe Direct Switch from Emicizumab in Phase 3b Hemophilia A Trial

a day ago
6

EMA Recommends Approval of Alvotech's Biosimilar to Eylea for Eye Disorders

10 hours ago
7

GLP-1 Diabetes Drug Liraglutide Reduces Migraine Days by Half in Pilot Study

3 days ago
8

Roche's NXT007 Achieves Zero Bleeds in Phase I/II Hemophilia A Trial, Advances to Phase III

15 hours ago
9

XtalPi Secures $100 Million Partnership with Harvard's Gregory Verdine to Advance AI-Driven Drug Discovery

19 hours ago
10

Vertex and Ono Pharmaceutical Form Strategic Alliance for Povetacicept Development in Japan and South Korea

10 hours ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy